Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926598 | 0.81 | TDP1 (0.47) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL27218406 | 0.77 | NPC1 (0.45) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL15286657 | 0.76 | NPC1 (0.55) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL12157404 | 0.75 | ALDH1A1 (0.53) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL31119754 | 0.74 | IKBKB (0.56) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL8863408 | 0.74 | DYRK1A (0.49) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL4789752 | 0.74 | MAPT (0.65) | KDM4ENPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL11868826 | 0.73 | TERT (0.49) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL22229945 | 0.72 | KMT2A (0.46) | KDM4ENPC1RAB9ATDP1MAPT | |
| SCHEMBL21160451 | 0.72 | PDE10A (0.43) | KDM4ENPC1RAB9AHKDC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2008051637-A2 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007150001-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150001-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | HAVCR2, PLPBP, CYP3A43 | KDM4E 3033/4885NPC1 688/4885RAB9A 3907/4885 |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | KDM4E 3649/4885NPC1 493/4885RAB9A 1991/4885 |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | KDM4E 3649/4885NPC1 493/4885RAB9A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.